Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of toll-like receptor 9

Clinical Cancer Research

Volumn 15, Issue 5, 2009, Pages 1575-1584

  Aurisicchio, Luigi ^a,d   Peruzzi, Daniela ^a   Conforti, Antonella ^a   Dharmapuri, Sridhar ^a   Biondo, Antonella ^a   Giampaoli, Saverio ^a   Fridman, Arthur ^b   Bagchi, Ansu ^b   Winkelmann, Christopher T ^b   Gibson, Raymond ^b   Kandimalla, Ekambar R ^c   Agrawal, Sudhir ^c   Ciliberto, Gennaro ^a   Monica, Nicola La ^a  

^a Merck Research Laboratories   (Italy)

^b MERCK RESEARCH LABORATORIES   (United States)

^c HYBRIDON INC   (United States)

^d Istituto di Ricerche di Biologia Molecolare   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALKALINE PHOSPHATASE; CANCER VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A; IMMUNOMODULATORY OLIGONUCLEOTIDE; IOHEXOL; PLASMID DNA; PROTEIN ANTIBODY; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER SIZE; CANCER SURVIVAL; CARCINOMA IN SITU; CD8+ T LYMPHOCYTE; CELL ACTIVATION; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA MICROARRAY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; ELECTROPORATION; ENZYME RELEASE; FEMALE; IMMUNOREACTIVITY; INJECTION SITE REACTION; INTERFERON PRODUCTION; LYMPHADENOPATHY; MICROARRAY ANALYSIS; MONOTHERAPY; MOUSE; NATURAL KILLER CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SERUM; TRANSGENIC MOUSE; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR IMMUNITY;

ADENOVIRIDAE; ALKALINE PHOSPHATASE; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN-PRESENTING CELLS; COMBINED MODALITY THERAPY; DIMERIZATION; DNA; ELECTROPORATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; INTERLEUKIN-12; KILLER CELLS, NATURAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PLASMIDS; POSITRON-EMISSION TOMOGRAPHY; RATS; RECEPTOR, ERBB-2; TOLL-LIKE RECEPTOR 9; VACCINES, DNA;

EID: 63449142715     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2628     Document Type: Article

References (51)

1. Prud'homme GJ. DNA vaccination against tumors. J Gene Med 2005;7:3-17.
2. Stephenson J. Defective adenoviruses as novel vaccines for the flaviviridae. Clin Diagn Virol 1998;10: 187-94.
3. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415: 331 -5.
4. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003;77: 799-803.
5. Casimiro DR, Bett AJ, FuTM, et al. Heterologous human immunodeficiency virus type1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 2004;78:11434-8.
6. Aurisicchio L, Mennuni C, Giannetti P, et al. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 2007;120:2290-300.
7. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96.
8. Berinstein NL. Enhancing cancer vaccines with immunomodulators. Vaccine 2007;25 Suppl 2: B72-88.
9. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987-95.
10. Daubenberger CA. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines. Curr Opin Mol Ther2007;9:45-52.
11. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008;27:161 -7.
12. Sparwasser T, Vabulas RM, Villmow B, Lipford GB, Wagner H. Bacterial CpG-DNA activates dendritic cells in vivo: Thelper cell-independent cytotoxicTcell responses to soluble proteins. Eur J Immunol 2000; 30:3591 -7.
13. Chaperot L, Blum A, Manches O, et al.Virusor TLR agonists induceTRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 2006;176: 248-55.
14. Ballas ZK. Modulation of NK cell activity by CpG oligodeoxynucleotides. Immunol Res2007;39:15-21.
15. Agrawal S, Kandimalla ER. Synthetic agonists of TLR7, 8and 9. Biochem Soc Trans 2007;35:1461 -7.
16. Kandimalla ER, Bhagat L, Li Y, et al. Immunomodulatory oligonucleotides containing a cytosinephosphate-2′-deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists. Proc Natl Acad Sci USA 2005;102:6925-30.
17. Kandimalla ER, Bhagat L, Zhu FG, et al. Adinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A 2003;100:14303-8.
18. Wang D, Kandimalla ER, Yu D, Tang JX, Agrawal S. Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity. Vaccine 2005; 23:2614-22.
19. Wang D, Li Y, Yu D, Song SS, Kandimalla ER, Agrawal S. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs. Int J Oncol 2004;24:901 -8.
20. Domiano V, Caputo R, Bianco R, et al.Novel Toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 2006; 12:577-83.
21. Damiano V, Caputo R, Garofalo S, et al. TLR9agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. Proc Natl Acad Sci U S A2007;104: 12468-73.
22. Moore D, Hwang J, Malik S, et al. Phase I trial of escalating doses of the TLR9 agonist HYB2055 in patients with advanced solid tumors. J Clin Oncol ASCO Annu Meet Proc 2005;23:2503.
23. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast andovarian cancer. Science1989;244:707-12.
24. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987;235:177-82.
25. Shak S; Herceptin Multinational Investigator Study Group. Overviewof the trastuzumab (Herceptin) anti- HER2 monoclonal antibody clinical program in HER2- overexpressing metastatic breast cancer. Semin Oncol 1999;26:71 -7.
26. Agus DB, Gordon MS, Taylor C, et al. PhaseI clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43.
27. Herbst RS, Davies AM, Natale RB, et al.Efficacy and safety of single-agent pertuzumab, ahuman epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin Cancer Res 2007;13: 6175-81.
28. Agus DB, Sweeney CJ, Morris MJ, et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 2007;25:675-81.
29. de Bono JS, Bellmunt J, Attard G, et al.Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapynaive patients with hormone-refractory prostate cancer. J Clin Oncol 2007;25:257-62.
30. Attard G, Kitzen J, Blagden SP, et al. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. Br J Cancer 2007;97: 1338-43.
31. Lucchini F, Sacco MG, Hu N, et al. Early and multi-focal tumors in breast, salivary, Harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Lett 1992;64:203-9.
32. Gallo P, Dharmapuri S, Nuzzo M, et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. IntJCancer2005;113:67-77.
33. Cipriani B, Fridman A, Bendtsen C, et al. Therapeutic vaccination halts disease progression in BALB-Neu T mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum GeneTher 2008; 19:670-80.
34. Rizzuto G, Capelletti M, Maione D, et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci U S A1999;96:6417-22.
35. Giannetti P, Facciabene A, La Monica N, Aurisicchio L. Individual mouse analysis of the cellular immune response to tumor antigens in peripheral blood by intracellular staining for cytokines. J Immunol Methods 2006;316:84-96.
36. ChoH S, Mason K, Ramyar KX, et al.Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421: 756-60.
37. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, deVos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-28.
38. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther 2007;7:1225-41.
39. Quaglino E, Iezzi M, Mastini C, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in HER-2/neu transgenic mice. Cancer Res 2004;64:2858-64.
40. Cavallo F, Offringa R, van der Burg SH, Forni G, Meilief CJM. Vaccination for treatment and prevention of cancer in animal models. In: Allison DJ, editor. Advances in immunology cancer immunotherapy. New York: Elsevier; 2005. p. 175-206.
41. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by theprogression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 2003;102:2138-45.
42. Nanni P, Landuzzi L, Nicoletti G, et al. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-γ and B cell dependent. J Immunol 2004;173:2288-96.
43. + Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005;174:4228-36.
44. Mittendorf EA, Storrer CE, Foley RJ, et al. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 2006;106:2309-17.
45. PeoplesGE, Gurney JM, Hueman MT, et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005;23:7536-45.
46. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008;57:1511 -21.
47. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 2006;13: 1085-98.
48. Roda JM, Parihar R, Carson WE III. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 2005;175:1619-27.
49. Lee-Hoeflich ST, Crocker L, Yao E, et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008;68: 5878-87.
50. Allen SD, Garrett JT, Rawale SV, et al. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007;179:472-82.
51. Garrett JT, Rawale S, Allen SD, et al. Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu.J Immunol2007;178:7120-31.